Related Experiment Video

Updated: May 25, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Romidepsin in the treatment of cutaneous T-cell lymphoma

Salvia Jain1, Jasmine Zain

  • 1NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, USA.

Journal of Blood Medicine
|January 31, 2012
PubMed

Insights

Romidepsin offers a new treatment option for advanced cutaneous T-cell lymphoma (CTCL). This well-tolerated histone deacetylase inhibitor shows promising activity and was FDA-approved in 2009 for patients with prior systemic therapy.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Primary cutaneous T-cell lymphoma (CTCL) encompasses mycosis fungoides and Sézary syndrome.
  • CTCL presents with variable clinical manifestations and prognosis.
  • Improving management of incurable CTCL with limited toxicity is a research priority.

Purpose of the Study:

  • To review the activity, pharmacology, and safety of romidepsin for CTCL treatment.
  • To highlight romidepsin's role in managing advanced-stage CTCL.

Main Methods:

  • Review of existing literature on romidepsin's efficacy and safety in CTCL.
  • Analysis of pharmacological properties and clinical trial data.

Main Results:

  • Romidepsin demonstrates promising activity against advanced CTCL.
  • It is a well-tolerated histone deacetylase inhibitor.
  • FDA approved in 2009 for CTCL patients post-systemic therapy.

Conclusions:

  • Romidepsin is an effective and well-tolerated treatment option for advanced CTCL.
  • Its approval signifies a step forward in managing this challenging disease.
Keywords:
HDACisT-cell lymphomapatientsromidepsin

More Related Videos

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...